Tempest Therapeutics Inc (TPST) USD0.001

Sell:$6.80Buy:$7.22$0.14 (2.00%)

Prices delayed by at least 15 minutes
Sell:$6.80
Buy:$7.22
Change:$0.14 (2.00%)
Prices delayed by at least 15 minutes
Sell:$6.80
Buy:$7.22
Change:$0.14 (2.00%)
Prices delayed by at least 15 minutes

Company Information

About this company

Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are Amezalpat and TPST-1495. Amezalpat is an oral, small molecule, selective antagonist of peroxisome proliferator-activated receptor alpha. The ongoing global randomized Phase Ib/II trial of Amezalpat combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma. The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, a pathway implicated in multiple cancers.

Key people

Stephen R. Brady
President, Chief Executive Officer, Director
Samuel Whiting
Executive Vice President, Chief Medical Officer
Nicholas Maestas
Vice President - Strategy and Finance, Corporate Secretary
Sheldon Mullins
Vice President - Regulatory Affairs
Troy M. Wagner
Vice President - Quality Assurance
Michael Raab
Independent Chairman of the Board
Geoffrey M. Nichol
Independent Director
Christine A. Pellizzari
Independent Director
Ronit Simantov
Independent Director
Click to see more

Key facts

  • EPIC
    TPST
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US87978U2078
  • Market cap
    $25.55m
  • Employees
    24
  • Shares in issue
    3.66m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.